DiaGen AI
DiaGen AI is a Vancouver-based AI drug-discovery company operating two validated platforms — Blackcomb for small molecules and Cypress for peptides — serving pharmaceutical, biotech, and academic research customers through platform licensing and research collaborations across four global regions.
- Company typePrivate
- Founded2021
- HeadquartersVancouver, Canada
- Headcount1–10
- GTM typeB2B
- OfferingSoftware
What DiaGen AI does
DiaGen AI Inc. is a Vancouver-based, privately held tech-bio company developing AI-driven platforms for small-molecule and peptide drug discovery, founded in 2021 and operating with a 1-10 person team. Its product portfolio centers on two proprietary platforms: Blackcomb, an atomic-resolution foundation model trained on 6.75M molecules that uses flow-network generation to produce novel, patentable small-molecule analogs (validated by the UNC Structural Genomics Consortium on KRAS-G12D degradation), and Cypress, an end-to-end in silico peptide discovery pipeline covering hotspot identification, backbone and sequence design, and molecular-dynamics validation (validated via a stable 30-mer C-reactive protein complex at 100-ns MD). The company has additionally published peer-reviewed work on AI biological age clocks using biomarkers (CRP, IGF-1, IL-6, GDF-15) combined with continuous biosensor monitoring, extending its surface into health-monitoring applications.
DiaGen AI generates revenue primarily through AI platform licensing to pharmaceutical and biotech companies and through strategic research collaborations with academic and medical institutions; pricing is not publicly disclosed and the product website remains in a 'coming soon' state. Its go-to-market combines direct B2B enterprise sales with a partnership-driven distribution model, including a joint venture with Metanova Labs for a decentralized hit-picking tool on the Bittensor network, an AKT Health partnership for Asia-Pacific/MENA/North America market expansion, and NVIDIA Inception for compute support.
The company is led by Chairman & CEO Brian D. Keane (JD), with Eldad Haber as CSO and Co-Founder and Elliot Holtham as COO, AI Lead, and Co-Founder. It maintains seven active partnerships across four geographic regions (North America, Europe, MENA, Asia-Pacific), has raised approximately $2M in disclosed funding (March 2024), and reports eleven independent recognitions validating its platform credibility.
DiaGen AI firmographics
Firmographics- Name
- DiaGen AI
- Legal name
- DiaGen AI Inc.
- Website
- https://diagen.ai
- Company type
- Private
- Founded year
- 2021
- Operating status
- Operating
- Headcount range
- 1–10 employees
- Short description
- DiaGen AI is a Vancouver-based AI drug-discovery company operating two validated platforms — Blackcomb for small molecules and Cypress for peptides — serving pharmaceutical, biotech, and academic research customers through platform licensing and research collaborations across four global regions.
- Ownership category
- akta.pro rank
DiaGen AI industry classification
Industry- Product category
- AI Drug Discovery
- NAICS
- Research and Development in Biotechnology (except Nanobiotechnology) (541714), Scientific Research and Development Services (5417)
- SIC
- Medicinal Chemicals & Botanical Products (2833), Biological Products, (No Disgnostic Substances) (2836)
- akta.pro primary industry
- AI/ML Platforms for Drug Discovery & Experiment Optimization (HLAGAJAO)
- akta.pro secondary industries
- Drug Discovery (Target ID/Validation & Hit Discovery) (HLAIALAA), Cheminformatics & Molecular Modeling / CADD (HLAGAJAE), Protein Engineering & Directed Evolution Platforms (enzyme/therapeutic protein optimization) (HLAAAIAC)
Keywords
Where DiaGen AI is headquartered
LocationHeadquarters
- HQ city
- Vancouver
- HQ country
- Canada
- HQ region
- North America
Offices1 record
Markets served
DiaGen AI business model
Business model- GTM type
- B2B
- Offering type
- Software
- Cost components
- Technology or R&D, Personnel, Infrastructure, Marketing or Sales, Operations
Revenue model
- AI Platform Licensing: Licensing of Blackcomb and Cypress AI platforms to pharmaceutical and biotech companies for drug discovery applications. Revenue generated through technology access fees, platform usage charges, and ongoing collaboration payments.
- Strategic Research Collaborations: Revenue from research collaborations with academic institutions, medical centers, and strategic partners. Includes co-development projects, validation studies, and joint venture arrangements such as the Metanova Labs partnership for hit-picking tool development.
Go-to-market motion3 records
Distribution channels1 record
Marketing channels4 records
DiaGen AI product offering
Product offeringCore offering
DiaGen AI develops and licenses two AI-driven drug discovery platforms: Blackcomb, an atomic-resolution foundation model trained on 6.75M molecules that generates novel, patentable small-molecule analogs through flow-network exploration of chemical space, and Cypress, an end-to-end in silico peptide discovery pipeline covering hotspot identification, backbone and sequence design, and molecular dynamics validation to find the strongest binders among billions of candidates. The platforms are sold and licensed to pharmaceutical, biotechnology, and academic research customers for accelerating therapeutic compound discovery.
Product overview
DiaGen AI offers a dual-platform architecture for AI-powered small-molecule and peptide drug discovery. The Blackcomb platform focuses on small molecules, using an atomic-resolution foundation model trained on 6.75M molecules with flow-network generation to produce novel, patentable analogs. The Cypress platform addresses peptide discovery through an end-to-end computational pipeline covering hotspot identification, backbone and sequence design, and molecular-dynamics validation. Both platforms are validated and deployed with clinical, academic, commercial, and decentralized partners across four global regions (North America, EU, MENA, APAC).
Differentiator
Problem solved
Functional benefit
Brands
- Blackcomb: An atomic-resolution foundation model trained on 6.75M molecules for small molecule drug discovery. Flow-network generation explores the chemical space next to a lead compound and returns novel, patentable analogs. Validated with degradation of mutant KRAS-G12D confirmed in cells by the Structural Genomics Consortium at UNC.
- Cypress
Products and services
- Blackcomb Atomic-resolution foundation model platform for small molecule drug discovery, trained on 6.75M molecules. Uses flow-network generation to explore chemical space around a lead compound and returns novel, patentable small-molecule analogs. Sold and licensed to pharmaceutical and biotechnology companies and research institutions for therapeutic compound discovery.
- Cypress End-to-end in silico peptide discovery pipeline including hotspot identification, backbone generation, sequence optimization, and molecular dynamics validation. Identifies the strongest binder among billions of peptide candidates on reduced compute. Deployed with research collaborators including Hadassah Medical Center and Ariel University, and licensed to pharma and biotech customers for peptide-based therapeutic design.
Quantifiable outcome
- Blackcomb platform validated: Degradation of mutant KRAS-G12D confirmed in cells by UNC Structural Genomics Consortium
- +1 more outcomes
Companies that use DiaGen AI
Customer profileNamed customers2 records
Segments2 records
Ideal customer profiles2 records
DiaGen AI technology and API
TechnologyTechnology focussed Yes
API detail
- Has API
- No
- API docs
- API detail
Core technology
AI maturity
App detail
AI capability5 records
Feature4 records
DiaGen AI partnerships and signals
Strategic signalPartnerships
Nine partnerships are on record, tiered core and supporting.
- AKT HealthcoreMarket expansion partnership leveraging AKT Health's established global networks across Asia-Pacific, Middle East, and North America for commercializing DiaGen AI's drug discovery platforms. Advisory board appointment of Aditya Tallapragada provides strategic guidance for UAE and regional expansion.
- MetaNova LabscoreJoint venture under LOI to develop multi-objective hit-picking tool integrating DiaGen's AI and bioinformatics expertise with Metanova's NOVA decentralized virtual screening platform built on Bittensor network. Joint IP development and revenue sharing from external applications including token-gated compound libraries for biotech and pharma clients.
- Hadassah - HadasitcoreResearch collaboration with Hadassah Medical Center's technology transfer company Hadasit for peptide-based therapeutic design using the Cypress platform.
- Ariel UniversitysupportingAcademic research collaboration with Ariel University in Israel for AI-driven peptide drug discovery research.
- UNC Structural Genomics ConsortiumcoreValidation partner who confirmed degradation of mutant KRAS-G12D in cells using Blackcomb platform, providing independent third-party validation.
- MilasupportingAI research collaboration with Mila (Quebec AI Institute) for advancing AI-driven drug discovery methodologies.
- Contango / General TensorsupportingStrategic partnering and investment relationship for technology commercialization and market development.
- NVIDIA InceptionsupportingAI technology partnership through NVIDIA Inception startup program for computational infrastructure support and GPU-accelerated AI development.
- Frontier IP GroupsupportingIntellectual property and commercialization partnership for protecting and commercializing AI-designed therapeutic compounds.
Scale indicators5 records
Recent moves6 records
Expansion highlights6 records
DiaGen AI competitors and assessment
Company assessmentDirect peers
- Atomwise: Atomwise operates an AI-driven small-molecule drug discovery platform using atom-level modeling — conceptually the closest direct competitor to DiaGen's Blackcomb platform, serving the same pharma/biotech enterprise buyer with similar computational chemistry workflows.
- Insilico Medicine: Insilico Medicine runs an end-to-end AI drug discovery platform covering target identification, small-molecule generation, and clinical development — directly comparable to Blackcomb's full-pipeline ambition and overlapping enterprise pharma customers.
- XtalPi: XtalPi combines AI, quantum physics, and robotics for small-molecule drug discovery, competing head-on with Blackcomb in AI-driven small molecule generation and serving similar pharma partners.
- Cradle Bio: Cradle focuses on AI-driven protein engineering and biologics design — directly comparable to DiaGen's peptide-focused Cypress platform, serving biologics discovery teams with generative protein design.
- Iambic Therapeutics: Iambic (formerly Entos) develops AI platforms for small-molecule drug discovery using physics-informed neural networks — directly comparable methodology and target customer overlap with Blackcomb.
Broad incumbents
- Schrödinger: Schrödinger is a broad computational chemistry and pharma software incumbent with a much wider portfolio (molecular simulation, LiveDesign, drug discovery services). It competes with DiaGen in pharma R&D but serves a much broader swath of the pharma software stack.
- Recursion Pharmaceuticals: Recursion combines AI with high-throughput wet-lab experimentation for drug discovery at much larger scale, with both internal pipeline and platform partnerships — overlapping with DiaGen's enterprise platform strategy but operating at substantially greater scale.
- Isomorphic Labs: Isomorphic Labs is Alphabet/DeepMind's commercial drug discovery arm, applying AlphaFold-derived methods to pharma R&D. As a deep-pocketed incumbent using AI structural biology for therapeutics, it overlaps with DiaGen's protein-and-binder design workflow.
Emerging players
- EvolutionaryScale: EvolutionaryScale builds frontier foundation models for biology/ proteins with a comparable wet-lab-free generative protein design angle to DiaGen's Cypress platform — emerging direct competitor in AI protein design.
- Peptone Therapeutics: Peptone focuses specifically on AI-driven intrinsically disordered protein and peptide therapeutics — narrow but direct overlap with DiaGen's peptide (Cypress) therapeutic design focus.
Market position
Strengths5 records
Weaknesses5 records
Competitive moat4 records
Key risks6 records
Key highlights7 records
Customer concentration
DiaGen AI social profiles
Digital presenceDiaGen AI financial estimates
Financial estimateRevenue estimate
Valuation estimate
DiaGen AI leadership team
Management profileNumber of profiles
Profiles4 records
DiaGen AI funding detail
Funding detailFunding overview
Funding rounds1 record
Investors
Funding detail is available on the Subscription and Enterprise plan.Contact sales →
DiaGen AI M&A and investment
M&A and investmentM&A
Investments
M&A and investment is available on the Subscription and Enterprise plan.Contact sales →
Frequently asked questions about DiaGen AI
What does DiaGen AI do?
DiaGen AI develops and licenses two AI-driven drug discovery platforms: Blackcomb, an atomic-resolution foundation model trained on 6.75M molecules that generates novel, patentable small-molecule analogs through flow-network exploration of chemical space, and Cypress, an end-to-end in silico peptide discovery pipeline covering hotspot identification, backbone and sequence design, and molecular dynamics validation to find the strongest binders among billions of candidates. The platforms are sold and licensed to pharmaceutical, biotechnology, and academic research customers for accelerating therapeutic compound discovery.
Is DiaGen AI a public or private company?
DiaGen AI is a private company. It is classified as founder individual operated bootstrapped and is currently operating.
When was DiaGen AI founded?
DiaGen AI was founded in 2021. It employs 1 to 10 people.
Where is DiaGen AI based?
DiaGen AI is headquartered in Vancouver, Canada, in the North America region.
How does DiaGen AI make money?
Two revenue lines are on record. AI Platform Licensing is the primary driver. The others are strategic Research Collaborations.
Who are DiaGen AI's main competitors?
Direct peers on record are Atomwise, Insilico Medicine, XtalPi, Cradle Bio and Iambic Therapeutics. Broad incumbents are Schrödinger, Recursion Pharmaceuticals and Isomorphic Labs. Emerging players are EvolutionaryScale and Peptone Therapeutics.
Does DiaGen AI have an API?
No public API is recorded for DiaGen AI.
What industry is DiaGen AI in?
DiaGen AI's product category is AI Drug Discovery. Its primary akta.pro industry code is HLAGAJAO, AI/ML Platforms for Drug Discovery & Experiment Optimization, with a secondary code of HLAIALAA, Drug Discovery (Target ID/Validation & Hit Discovery). Its NAICS code is 541714 and its SIC code is 2833.